This study will be an open-label, randomised, 3-period, 3-treatment, crossover study in healthy subjects (males and females of non-childbearing potential), performed at a single Clinical Unit.~The study will comprise:~A Screening period of 28 days.~Three periods during which subjects will participate from Day -1 of Period 1 to 72 hours after the nintedanib dose in Period 3. In each period, the subjects will receive nintedanib in the morning of Day 1. In treatment sequences in which AZD5055 will be co administered with nintedanib, AZD5055 will be administered immediately before the nintedanib dose on Day 1.~A Follow-up Visit, 6 ±1 days after the last dose of nintedanib in the last period.~All subjects will be randomised 1:1:1 to 3 sequences (ABC, BCA, CAB). Each sequence consists of three treatment periods (Period 1, Period 2, Period 3).~Treatment A: Nintedanib soft capsules, fasted state. Treatment B: Dose B oral suspension of AZD5055 will be given immediately followed by nintedanib soft capsules in the fasted state.~Treatment C: Dose C oral suspension of AZD5055 will be given immediately followed by nintedanib soft capsules in the fasted state.
The study is intended to quantify the effect of co-administration of AZD5055 on exposures of nintedanib in healthy subjects.